PROCEPT BioRobotics Corporation Class Action Lawsuit

U.S. Securities Litigation

Procept Class Action Lawsuit Allegations

The Procept class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Procept common stock. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned *Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, et al.*, No. 26-cv-7691.

If you lost money on your Procept investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is Procept Being Sued for Securities Fraud?

Procept has been sued for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. The decline in Procept's stock price caused significant losses to investors.

Procept is a medical technology company that sells surgical devices used in the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate. The company's devices perform its Aquablation therapy—a robotically controlled, image-guided waterjet procedure that removes excess prostate tissue. Procept sells its robotic system as well as handpieces, which are the single-use disposable instruments used during each procedure.

During the relevant period, Procept stated that utilization of its devices was increasing, which represented "growing" demand for the company's technology. Procept also represented that its handpiece sales were in line with the number of procedures performed. The company stated that its customers "tend to order as they need [a] product." The company also stated that the "differential" between procedures and handpiece sales had "remained relatively consistent."

As alleged, Procept's sales were driven by an extensive discount program that incentivized customers to place bulk handpiece orders in excess of underlying procedures. Procept's discount program had caused handpiece orders to materially exceed procedures in every quarter during the relevant period.

Why did Procept's Stock Drop?

On August 6, 2025, Procept announced fiscal Q2 2025 results, revealing that handpiece unit shipments had unexpectedly deteriorated. Procept also disclosed that it expected to ship 13,350 handpieces the following quarter. This news caused the price of Procept stock to decline $7.28 per share, or 16% over a two-day trading period, from a closing price of $45.69 per share on August 6, 2025, to $38.41 per share on August 8, 2025.

On November 4, 2025, Procept announced fiscal Q3 2025 results, revealing that it was reducing annual handpiece sales guidance by 1,000 units to allow for the "optimization of field inventory" and admitted that some customers were "probably carrying too much" inventory. This news caused the price of Procept stock to decline $3.72 per share, or 10% over a two-day trading period, from a closing price of $35.02 per share on November 4, 2025, to $31.30 per share on November 6, 2025.

Then, on February 25, 2026, Procept announced fiscal Q4 2025 results, revealing that U.S. handpiece unit sales had materially exceeded procedures in every quarter since Q1 2023, resulting in cumulative excess field inventory of more than 10,000 units. The company also revealed that U.S. handpiece unit sales had contracted by approximately 30%. This news caused the price of Procept stock to decline $5.15 per share, or 18% over a two-day trading period, from a closing price of $27.84 per share on February 25, 2026, to $22.69 per share on February 27, 2026.

Procept ($PRCT) Stock Chart

Image Caption: NASDAQ online chart showing the Procept (PRCT) stock drops following the August 2025, November 2025, and February 2026 announcements.

What is the Procept Lead Plaintiff Deadline?

You may ask the Court no later than September 22, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information?

If you lost money when Procept securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall
amccall@bfalaw.com
212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*.

BFA attorneys have been named "Elite Trial Lawyers" by the *National Law Journal*, "Litigation Stars" by *Benchmark Litigation*, among the top "500 Leading Plaintiff Financial Lawyers" by *Lawdragon*, "Titans of the Plaintiffs' Bar" by *Law360*, and "SuperLawyers" by *Thomson Reuters*.

Most recently, *The Legal 500* awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.